SELLAS Q3: $134.7M Cash, $28.1M Nine-Month Loss, REGAL Topline Due November
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS ended Q3 with $134.7 million in cash, enough for at least twelve months, while its nine-month net loss widened to $28.1 million on higher BLA-prep and trial spending. REGAL topline results are expected in November 2026.
Key Events · Earnings and Guidance · SLS
-
Cash Position Rises to $134.7M
Cash and cash equivalents reached $134.7 million at September 30, 2026, up from $71.8 million at December 31, 2025, after $85.1 million of warrant-exercise proceeds.
-
Nine-Month Net Loss Widens
The nine-month net loss was $28.1 million versus $19.2 million a year earlier, as R&D rose to $18.4 million from $11.3 million on BLA preparation and SLS009 enrollment.
-
Runway Through at Least Twelve Months
Management expects cash to fund planned operations for at least the next twelve months from issuance, with no going-concern doubt; the $150.0 million 2026 ATM remains unused.
-
REGAL Topline Expected November 2026
The 80th death event triggered the final REGAL analysis; preliminary topline primary endpoint results are expected in November 2026.
Analysis · SLS · Life Sciences
The balance sheet is the story: $134.7 million of cash at September 30, 2026, up from $71.8 million at year-end on $85.1 million of warrant-exercise proceeds, and management says that funds planned operations for at least twelve months. That removes near-term financing pressure heading into the REGAL final analysis, whose topline primary endpoint results are expected in November 2026 — the binary event that will decide the stock. Spending is climbing as the company preps a potential GPS BLA and enrolls the SLS009 first-line AML trial, so the nine-month net loss widened to $28.1 million from $19.2 million, but the $150 million ATM is untouched and the 3D Medicines arbitration is behind it at a ~$1.0 million cost.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLS was trading at $8.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $1.39 to $15.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.